Rigosertib

Rigosertib

SCHEMBL4726480

COc1cc(OC)c(C=CS(=O)(=O)Cc2ccc(OC)c(NCC(=O)[O-])c2)c(OC)c1.[Na+]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Rigosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 4/20 1.00
MET P08581 1/20 0.81
NQO2 P16083 1/20 0.81
FECH P22830 1/20 0.81
CLK3 P49761 1/20 0.81
HDAC8 Q9BY41 3/20 0.78
HDAC3 O15379 2/20 0.78
HDAC4 P56524 2/20 0.78
HDAC1 Q13547 2/20 0.78
HDAC7 Q8WUI4 2/20 0.78
HDAC2 Q92769 2/20 0.78
HDAC10 Q969S8 2/20 0.78
HDAC11 Q96DB2 2/20 0.78
HDAC6 Q9UBN7 2/20 0.78
HDAC9 Q9UKV0 2/20 0.78
HDAC5 Q9UQL6 2/20 0.78
ABCG2 Q9UNQ0 1/20 0.39
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rigosertib SCHEMBL498729 1.00 PLK1 (1.00) PLK1METNQO2FECHCLK3
Rigosertib SCHEMBL29360545 1.00 PLK1 (1.00) PLK1METNQO2FECHCLK3
Rigosertib SCHEMBL29397572 0.90 PLK1 (1.00) PLK1METNQO2FECHCLK3
Rigosertib SCHEMBL498623 0.90 PLK1 (1.00) PLK1METNQO2FECHCLK3
SCHEMBL498448 0.90 PLK1 (0.84) PLK1METNQO2FECHCLK3
SCHEMBL498447 0.90 PLK1 (0.84) PLK1METNQO2FECHCLK3
Rigosertib SCHEMBL498624 0.90 PLK1 (1.00) PLK1METNQO2FECHCLK3
Rigosertib SCHEMBL498728 0.89 PLK1 (0.98) PLK1METNQO2FECHCLK3
Rigosertib SCHEMBL498730 0.89 PLK1 (0.98) PLK1METNQO2FECHCLK3
SCHEMBL15835693 0.85 PLK1 (0.77) PLK1METNQO2FECHCLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008027049-A1 COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-03-06 WO claimed
US-20180344736-A1 METHODS AND MATERIALS FOR TREATING CANCER ROCHESTER (US) 2018-12-06 US disclosed
WO-2017044615-A1 METHODS AND MATERIALS FOR TREATING CANCER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2017-03-16 WO disclosed
WO-2006104668-A2 COMPOSITION AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-10-05 WO disclosed